Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

6-1-2013

Expression of ski can act as a negative feedback mechanism on
retinoic acid signaling
Meaghan A. Melling
Children's Health Research Institute, London, ON

Charlotte R.C. Friendship
Children's Health Research Institute, London, ON

Trevor G. Shepherd
London Regional Cancer Program, trevor.shepherd@lhsc.on.ca

Thomas A. Drysdale
Children's Health Research Institute, London, ON, tadrysda@uwo.ca

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub
Part of the Pediatrics Commons

Citation of this paper:
Melling, Meaghan A.; Friendship, Charlotte R.C.; Shepherd, Trevor G.; and Drysdale, Thomas A.,
"Expression of ski can act as a negative feedback mechanism on retinoic acid signaling" (2013).
Paediatrics Publications. 1188.
https://ir.lib.uwo.ca/paedpub/1188

DEVELOPMENTAL DYNAMICS 242:604–613, 2013

RESEARCH ARTICLE

a

Expression of Ski Can Act as a Negative
Feedback Mechanism on Retinoic Acid
Signaling

Developmental Dynamics

Meaghan A. Melling,1,2 Charlotte R.C. Friendship,1,2 Trevor G. Shepherd,3,4 and
Thomas A. Drysdale1,2,5*

Background: Retinoic acid signaling is essential for many aspects of early development in vertebrates. To
control the levels of signaling, several retinoic acid target genes have been identified that act to suppress
retinoic acid signaling in a negative feedback loop. The nuclear protein Ski has been extensively studied
for its ability to suppress transforming growth factor-beta (TGF-b) signaling but has also been implicated
in the repression of retinoic acid signaling. Results: We demonstrate that ski expression is up-regulated in
response to retinoic acid in both early Xenopus embryos and in human cell lines. Blocking retinoic acid
signaling using a retinoic acid antagonist results in a corresponding decrease in the levels of ski mRNA.
Finally, overexpression of SKI in human cells results in reduced levels of CYP26A1 mRNA, a known target
of retinoic acid signaling. Conclusions: Our results, coupled with the known ability of Ski to repress retinoic acid signaling, demonstrate that Ski expression is a novel negative feedback mechanism acting on
C 2013 Wiley Periodicals, Inc.
retinoic acid signaling. Developmental Dynamics 242:604–613, 2013. V
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Key fingings:
 Addition of retinoic acid increases Ski transcript levels in Xenopus embryos and mammalian cells.
 Addition of a retinoic acid antagonist results in reduced levels of Ski transcripts in Xenopus embryos and
mammalian cells.
 Addition of retinoic acid appears to directly activate Ski expression.
 Over expression of Ski results in reduced transcript levels of the retinoic acid target gene, Cyp26a1.
Accepted 8 February 2013

INTRODUCTION
Retinoic acid (RA) is a key signaling
molecule for a wide range of developmental processes (Duester, 2008; Niederreither and Dolle, 2008). The
proper development of the embryo
requires a tight control over both the

spatial localization and levels of RA
signaling. During early embryogenesis, it appears that a primary mechanism for controlling both the levels of
RA and its spatial distribution is the
presence of Aldh1a2 (Raldh2), the
enzyme primarily responsible for the
conversion of all-trans retinaldehyde

into RA (Niederreither et al., 1999),
and Cyp26a1, the enzyme primarily
responsible for metabolizing RA to
inactive forms (Sakai et al., 2001).
Loss of either of Aldh1a2 (Niederreither et al., 1999) or Cyp26a1 (Sakai
et al., 2001) results in embryonic
lethality closely resembling, but not
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identical to the effects of loss of RA or
excess RA, respectively (Mark et al.,
2006). Later in development, closely
related enzymes will also regulate RA
levels (Niederreither and Dolle, 2008)
in addition to potential alternate
routes of generating RA (Chambers
et al., 2007).
The expression of Aldh1a2 and
Cyp26a1 can act as part of a negative
feedback loop that responds to
changes in RA levels. Exogenous retinoic acid will suppress expression of
Aldh1a2 (Niederreither et al., 1997)
and blocking RA signaling will result
in increased expression. Although
Cyp26 expression does not require
RA, addition of RA greatly increases
expression of Cyp26a1, whereas
reduced levels of RA results in a
marked reduction in expression (Hollemann et al., 1998; de Roos et al.,
1999; Sirbu et al., 2005; Ross and Zolfaghari, 2011). Negative feedback
loops also extend to the enzymes that
convert retinol to all-trans retinaldehyde (Strate et al., 2009; Feng et al.,
2010).
In addition to negative feedback at
the level of RA synthesis and degradation, regulation at the level of signaling has been demonstrated.
Retinoic acid acts by binding to
dimers of specific nuclear receptors,
the retinoid receptors (RARs) and retinoid X receptors (RXRs) that are
bound to target retinoid acid response
elements (RAREs). Binding of the
ligand to the receptor results in a
recruitment of chromatin remodeling
factors that promote activation of
transcription whereas the unbound
receptor complex is bound to repressors of transcription (Xu et al., 1999).
RIP140 is a co-repressor associated
with retinoic acid receptors and is
directly induced by RA (White et al.,
2003; Heim et al., 2007). Expression
of COUP-TF, encoding another nuclear receptor is directly induced by
RA and can compete with RAR-RXR
heterodimers on the Cdx1 promoter
thereby acting as a negative feedback
on RA induction of Cdx1 (Beland and
Lohnes, 2005).
Ski has also been associated with
suppression of the RA signaling pathway through interference with transcription by RARs (Dahl et al., 1998).
Ski is a nuclear protein that has been
associated with several transcription

factors, including Smads and Rb
where it acts as a repressor (Tokitou
et al., 1999; Luo, 2004; Takeda et al.,
2004), and myogenin, where it acts as
an activator (Zhang and Stavnezer,
2009). Both gain of function (Amaravadi et al., 1997; Kaufman et al.,
2000) and loss of function (Berk et al.,
1997) experiments suggest multiple
roles for Ski in normal development.
Analysis of acute myeloid leukemia
patients also found that the inability
to respond to RA therapies is correlated with high levels of SKI gene
expression (Teichler et al., 2008) and
suppression of RA signaling by Ski in
COS-1 cells is inhibited when its
NCoR binding domain is deleted (Ritter et al., 2006). Ski also colocalizes
with the repressor protein, HDAC3, a
major component of the co-repressor
complex associated with RARs that
are not bound by ligand. Degradation
of HDAC3 was inhibited by Ski, stabilizing the co-repressor complex associated with the RAR/RXR dimer bound
to the RARE (Zhao et al., 2009). The
inhibition is attributed to an interaction with Ski and the Seven in Absentia Homologue 2 protein, Siah2, a
component of the E3 ubiquitin ligase
pathway. Functional Siah2 promotes
the degradation of specific proteins,
including HDAC3 (Zhao et al., 2009).
Therefore, it is proposed that Ski
inhibits the degradation of the RA signaling repressor HDAC3 by the E3
ubiquitin ligase pathway, thereby inhibiting RA signaling. The Ski-interacting protein (Skip) has also been
implicated in the RA pathway. Skip is
a co-regulator of vitamin D receptor/
RXR signaling, and more recently has
been shown to activate RAR activity
by interacting with and stabilizing
nuclear co-activators and steroid receptor coactivator (SRC) complexes
(Barry et al., 2003; Kang et al., 2010).
Taken together, these results suggested to us the hypothesis that
expression of ski is a link in a negative feedback loop on RA signaling.
In this study, we have found that
RA up-regulates ski expression in
both Xenopus embryos and in mammalian cell lines. This regulation
appears to be direct and the increased
levels of ski appear to reduce levels of
RA signaling. Coupled with results
from other labs that have demonstrated the ability of Ski to repress

transcription through RARs, we provide evidence that Ski can act in a
negative feedback loop to modulate
RA signaling.

RESULTS
Expression of ski in Xenopus
Embryos
Although ski has been studied in Xenopus, particularly for its role in suppression of bone morphogenetic
protein (BMP) signaling (Sleeman
and Laskey, 1993; Amaravadi et al.,
1997; Wang et al., 2000; Luo, 2003),
the spatial expression of ski has not
been extensively described. Using
whole-mount in situ hybridization, we
were able to detect ski mRNA in the
mesodermal mantle at the beginning
of gastrulation and we could also find
strong expression in the forming anterior spinal cord and discrete regions
of the head. Later in development,
significant expression can be found in
a variety of sites, including the neural
crest, spinal cord, somites, and otic
vesicle (Fig. 1). The in situ images
suggest that expression may be quite
widespread at a low level, although
the regions of high expression were
very distinct.

Retinoic Acid Causes an
Increase in ski mRNA Levels
in Both Xenopus Embryos
and in Human Cells
If ski expression was part of a negative feedback loop that can regulate
RA signaling, then exposure to exogenous RA should increase expression
of ski. Xenopus embryos exposed to
1mM RA showed a marked increase in
staining when analyzed by wholemount in situ hybridization. This
increase was easily observed after 6–
10 hr of exposure and was observed at
all embryonic stages tested (Fig. 2).
Importantly, treatment with a panRAR antagonist (Teng et al., 1997)
resulted in a corresponding decrease
in ski expression as seen both by in
situ hybridization and real-time polymerase chain reaction (PCR) (Fig. 2),
suggesting that RA plays a role in the
regulation of ski expression in vivo.
The veracity of the retinoic acid treatment was confirmed by the marked
induction of cyp26a1 expression by
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Fig. 1. Endogenous expression of ski in Xenopus. Ski expression was first detectable in a
ring around the blastopore at stage 10/11. At
stage 20, strong expression was observed in
bands in the forming head in the anterior (ant.)
view There is also staining on the ventral midline immediately posterior to the cement gland
at that stage. In a dorsal view, strong staining
can be seen in the anterior spinal cord (black
arrow) and the staining can be seen even further posterior at stage 22. Strong staining was
also observed in the migrating anterior neural
crest (red arrowheads). At tail bud stages (St.
30) low levels of expression are seen over
much of the embryo including somites and
higher expression was still viewed in discrete
regions including the otic vesicle (yellow
arrow).

RA and loss of expression in the presence of the RA antagonist (Fig. 2C).
The increase in ski expression
appeared to be in all tissues as the
embryos showed increased expression
throughout the embryo. However,
regions of novel high expression were
also observed. In particular, in control
embryos, there was a consistent gap
in the expression of ski in the spinal
cord and expression of ski in the forming brain. When embryos were
treated with RA, the gap was no longer present and strong ski expression
was observed along the entire anterior–posterior axis of the nervous system (Fig. 3). As might be predicted,

Fig. 2. Exposure to retinoic acid (RA) causes an increase in ski expression. A: When Xenopus
embryos were exposed to 1mM retinoic acid from stage 14 to 20, stage 20 to 26, or from stage
26 to 32, there was an increase in ski expression as assayed by whole-mount in situ hybridization. If embryos were exposed to 1 mM retinoic acid antagonist expression of ski was reduced.
This was particularly evident in the pharyngeal region (red arrows). B: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) for expression of ski in Xenopus embryos
treated as mentioned previously between stages 14–20. Ski is significantly up-regulated in
response to RA and down-regulated in embryos treated with RA antagonist. C: Positive control
quantifying expression of downstream RA signaling target cyp26a1 in response to RA or RA antagonist treatment showing the expected increase and decrease (respectively) in expression.
qRT-PCR is normalized to h4 mRNA levels. mRNA levels were normalized to the h4 housekeeping gene. Error bars represent standard error of the mean. n ¼ 5. *P < 0.05 **P < 0.01.

the strong expression in the developing spinal cord was much reduced
when embryos treated with the RA
antagonist (Fig. 3).
Inhibition of aldh1a2 in embryos
using either citral or diethylaminobenzaldehyde (DEAB), resulted in
reduced levels of cyp26a1 expression
as expected, although there were
regions that were expression was not
altered such as the tail bud region.
This treatment also resulted in
decreased expression of ski (Supp.
Fig. 1, which is available online). Inhibition of cyp26a1 by ketoconazole
treatment caused an increase in
cyp26a1 expression but we were not
able to conclude that ski expression

was increased based on the in situ
hybridization results. Taken together,
these results support the conclusion
that ski expression responds to
changes in RA levels under physiologically relevant conditions.
To test if the increase in ski expression in response to RA treatment was
a general phenomenon, we examined
ski expression in an immortalized
human keratinocyte (HaCaT) cell line
in response to altered RA signaling.
HaCaT cells were chosen because
they have previously been shown to
respond to both RA (Torma et al.,
1999; Boudjelal et al., 2002) and BMP
(Botchkarev, 2003; Gosselet et al.,
2007) signaling pathways. HaCaT
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Fig. 3. Different regions of the embryo responded differently to changes in retinoic acid (RA)
signaling. Addition of RA to embryos resulted in a general increase in staining by in situ hybridization, suggesting that the most cells are responding to the increased signaling. There was a
much greater response at specific sites. In particular, there is a gap in staining in the neural
tube (black arrowheads) roughly corresponding to the hindbrain. Addition of RA resulted in that
region showing very strong expression of ski as assayed by in situ hybridization. The posterior
spinal cord (blue arrow) does not normally have strong expression of ski but does so when RA
is added. When embryos are treated with an RA antagonist, the strong staining in the brain (red
arrow) and spinal cord (yellow arrows) is much reduced. Note that staining in the somites is also
markedly reduced in the antagonist treated embryos. DMSO, dimethyl sulfoxide.

cells express SKI endogenously and
have previously been used to manipulate SKI activity (Denissova and Liu,
2004; Suzuki et al., 2004; Levy et al.,
2007). Using quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR), a significant increase
(> two-fold) in SKI mRNA levels was
observed after 1 hr and that was
maintained for at least 8 hr after RA
treatment. Treatment with the panRAR antagonist caused a decrease in
endogenous SKI mRNA levels after 4
hr (Fig. 4A). The time course of
changes in SKI mRNA levels was similar to changes in the levels of
CYP26A1 mRNA, although the magnitude of change was much greater
with CYP26A1 expression and the
changes were sustained throughout
the 24-hr treatment (Fig. 4B). We

were also able to observe an increase
in levels of SKI protein after treatment with 1 mM RA. The increase
was observed after 8 hr and was sustained to at least 24 hr after exposure
to RA (Fig. 4C).

RA Directly Regulates
Expression of Ski
Given that the changes in ski expression roughly followed the time course
of changes in cyp26a1 expression, we
investigated whether RA might
directly activate ski expression as it
does cyp26a1. If embryos were cultured in the presence of 1 mM cycloheximide before and during the RA
treatment to block protein synthesis,
we still observed a significant
increase in the expression of ski, as

assayed both by in situ hybridization
and qRT-PCR (Fig. 5). The magnitude
of the change in mRNA levels was
somewhat reduced as compared to
previous
experiments
because
embryos could only be cultured for 2–
3 hr in cycloheximide due to toxicity.
Again the effectiveness of the RA and
cycloheximide treatment was demonstrated using expression of cyp26a1, a
known direct target of RA signaling
(Hollemann et al., 1998), as an assay.
The ability of RA to directly activate
ski expression extends to mammalian
cells, as HaCaT cells also up-regulated SKI expression in the presence
of cycloheximide (Fig. 6), although the
magnitude of the change was much
smaller than that observed for
CYP26A1 expression.
If ski acts in a negative feedback
loop that regulates RA signaling, we
would predict that overexpression of
Ski should inhibit the expression of
RA target genes. HaCaT cells were
transiently transfected with 2 mg of
either pCS2-FLAG-cSki or pCS2FLAG-Ski-ARPG, encoding a mutant
that is able to inhibit transforming
growth factor b (Tgfb) but not BMP
signaling (Takeda et al., 2004). As
expected, the transfection with the
Ski-FLAG construct resulted in
reduced expression of ID3, a direct
target of BMP signaling expression
(Hollnagel et al., 1999) whereas the
Ski-APRG-FLAG mutant did not.
Using qRT-PCR to quantify CYP26A1
mRNA levels, we found a significant
decrease in CYP26A1 expression in
cells transfected with either the SkiFLAG or Ski-APRG-FLAG constructs
when compared with controls (Fig.
7B).

DISCUSSION
RA signaling is essential for multiple
developmental events and the level of
signaling is critical to many of these
events (Duester, 2008; Niederreither
and Dolle, 2008). Given the necessity
for controlling the level of signaling,
it is not surprising that negative feedback loops have been identified that
limit the RA signaling once it has
been activated. The majority of the
identified feedback loops act at the
level of ligand availability as exemplified by the expression of aldh1a2 and
cyp26a1 (Niederreither et al., 1997;
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Fig. 4. Retinoic acid (RA) signaling affects SKI expression in vitro. A: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) of HaCaT cells treated for 15 min, 1 hr, 4 hr, 8
hr, or 24 hr with dimethyl sulfoxide (DMSO) control, or 1 mM RA or RA antagonist (RAA) quantifying changes in levels of SKI mRNA. B: Positive control of similarly treated cells quantifying
known downstream direct RA signaling target CYP26A1. mRNA levels were normalized to
GAPDH expression. C: Western blot showing increase in SKI protein levels in response to RA
treatment expression. Increases were noted after 8 hours of treatment compared with the control ACTIN levels. Error bars represent standard error of the mean. n ¼ 5. *P < 0.05, **P < 0.01.

Hollemann et al., 1998; Strate et al.,
2009; Feng et al., 2010; Ross and Zolfaghari, 2011). Here we identify the
transcriptional repressor ski as a
novel component of feedback loops on
RA signaling (Fig. 8). Ski expression
is directly up-regulated in response
to
addition
of
RA
in
both
Xenopus embryos (Figs. 2, 3) and in

mammalian cells (Fig. 4). Importantly, a normal role for RA in ski
expression is suggested by the reduction in expression when embryos are
exposed to an RA antagonist (Fig. 2)
or by changes in RA levels caused by
inhibition of aldh1a2, although it is
clear that RA is not the only factor
regulating its expression.

Our results using cycloheximide
suggest that retinoic acid can directly
activate the ski promoter in both Xenopus and mammalian cell lines. A
recent analysis of mouse embryonic
stem cells exposed to RA identified
Ski as one of the significantly upregulated genes. In addition, that
study used chromatin immunoprecipitation (ChIP) to identify several
enriched binding sites for RARs that
were associated with the transcriptional start site of the two protein
encoding
transcripts
of
Ski
(ENMUST00000030917,
ENMUST
00000084103), supporting our observations that Ski is directly regulated
by RA (Moutier et al., 2012). Given
that more than 10,000 potential binding sites were identified (Moutier
et al., 2012), confirmation of our suggestion that RA directly regulates Ski
will require ChIP analysis on Xenopus embryos and HaCaT cells followed by direct functional analysis of
identified binding sites.
We are also able to show that an
increase in Ski expression is able to
reduce the expression of the RA target gene cyp26a1 (Fig. 7). To complete
the feedback loop, a mechanism for
the ability of ski to interact with the
RA receptor to reduce RA signaling is
needed and at least one mechanism,
the association with and stabilization
of HDAC3, has been elucidated (Zhao
et al., 2009, 2010). This represents a
similar strategy to transforming
growth factor-beta (TGF-b)/BMP signaling where negative feedback loops
exist that reduce the ability of ligand
by activating expression of noggin,
while expression of Ski can be part of
negative feedback loop at the level of
the nucleus (Massague and Chen,
2000).
Our observations of a general low
level of ski expression in most tissues
with a high levels in the neural tube
and neural crest is in agreement with
that observed in mouse (Lyons et al.,
1994). It is likely that much of the
increase in expression in response to
RA exposure is due to the general
increase in expression throughout the
embryo. The marked increase in ski
expression in specific regions such as
the gap between the spinal cord and
brain staining is more likely due to
changes in tissue patterning rather
than the general increase in ski
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Fig. 5. Retinoic acid (RA) signaling directly alters ski expression in vivo. A: Whole-mount in situ hybridization of embryos pretreated with 20 min
of 1 mM cycloheximide to block translation followed by 1 hr treatment with 1 mM RA. In a dorsal view, embryos treated from St. 14–16 showed
increased staining with RA even in the presence of cycloheximide. Embryos treated from St. 26–28 (side view) showed the same result. B: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) of similarly treated embryos between stages 14 and 16 showed that ski expression is up-regulated by RA even in the presence of cycloheximide. C: qRT-PCR analysis of cyp26a1, a known direct target of RA signaling, was
used as a positive control for the RA and cycloheximide treatments. Error bars represent standard error of the mean. n¼5. *P < 0.05, **P < 0.01,
***P < 0.001.

expression. Posteriorization of anterior neural identities is a known
result of exposure to RA in Xenopus
(Sharpe, 1991; Chen et al., 2001).
The changes in ski expression that
we observed were much smaller than
the changes observed for the expression of cyp26a1. The greater response
by cyp26a1 may be necessary due to
the different mechanisms used to inhibit RA signaling. Cyp26a1 acts to
catabolize retinoic acid and may be
required at higher levels to have
enough activity to reduce RA levels
significantly. By acting within the nucleus to disrupt RA signaling, ski may
be able to act faster to modulate RA
signaling or perhaps be required at
relatively low levels. Rip140 (Nrip1)
is another nuclear co-repressor that
acts in a negative feedback loop to
suppress RA signaling (Heim et al.,
2007). Rather than simply inhibiting
the RA receptor, Rip140 expression
oscillates with time and also plays a
role in fine tuning the oscillatory
expression of other RA target genes
(Heim et al., 2009).

In mice, the loss of Ski results in a
wide variety of defects including exencephaly, facial clefting, reduced skeletal
muscle
mass,
abnormal
skeletogenesis, and ocular defects
(Berk et al., 1997; McGannon et al.,
2006). While it is tempting to attribute some of these observed defects to
excess RA signaling, the ability of Ski
to also modulate the activity of other
key genes that regulate development,
such as TGF-b and BMP signaling
(Luo et al., 1999; Takeda et al., 2004),
makes it extremely difficult to single
out a single pathway. Indeed, the upregulation of Ski by retinoic acid
could result in modulation of the activity of other pathways where Ski
plays a role, representing a potential
direct cross-talk between key developmental pathways. If some of the Ski
loss of function phenotypes in mice
(Berk et al., 1997; Colmenares et al.,
2002) can be attributed to an increase
in RA signaling, it is clearly different
than the phenotype observed when
Cyp26a1 is lost. In Cyp26a1 knockouts, mice exhibit severe truncations

at the posterior end of the embryo in
addition to homeotic mutations (Sakai
et al., 2001), suggesting that the ability of Ski to suppress RA signaling is
not as potent as that of Cyp26a1.
Our experiments demonstrate that,
in addition to being able to repress
RA signaling, expression of Ski is at
least partially regulated by RA. This
provides a novel negative feedback
loop on RA signaling and a potential
mechanism for cross-talk between important developmental pathways. The
challenge in future will be to determine the relative roles of these feedback
mechanisms
in
both
development and disease.

EXPERIMENTAL
PROCEDURES
Embryo Manipulations
Female Xenopus females were
induced to ovulate by injection of
500–600 IU of human chorionic gonadotropin depending on the size of
the animal and eggs were fertilized
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Fig. 6. Retinoic acid (RA) signaling directly
regulates ski expression in HaCaT cells. A:
Quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) of HaCaT cells
treated for 20 min with 1 mM cycloheximide
followed by 1 hr with 1 mM RA demonstrates
that RA significantly increases ski expression
even in the presence of cycloheximide in the
same manner as cyp26a1, a known direct target of RA signaling (B). Error bars represent
standard error of the mean. n ¼ 5. *P < 0.05,
**P < 0.01.

using minced testes in 80% Steinberg’s solution. Embryos were dejellied in 2.5% cysteine, pH 8.0, and
allowed to develop to the specified
stage in 20% Steinberg’s solution and
embryos were staged according to the
Nieuwkoop and Faber staging table
(Nieuwkoop and Faber, 1994).
Embryos were treated in 20% Steinberg’s solution at various stages using
1 mM all-trans retinoic acid (RA)
(Sigma), or 1 mM pan-retinoic acid antagonist (RAA) (Allergan 193109;
Teng et al., 1997) both diluted from a
1mM stock solution in dimethyl sulfoxide (DMSO). Thus, 1ml/ml DMSO
was used as a carrier control. Protein
synthesis was inhibited using 1mM
cycloheximide (Moreno and Kintner,
2004). When testing the effect of
blocking protein synthesis in conjunction with RA treatments, the cycloheximide was added for 20 min before
RA addition followed by 1-hr treatments with either DMSO or 1mM

Fig. 7. Overexpression of both Ski and the Ski-APRG mutant causes decreased expression of
CYP26A1. A: Western blot (anti-FLAG) confirming protein synthesis from the Ski and Ski-APRG
constructs after transfection into HaCaT cells. B: Quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) quantifying the levels CYP26A1 mRNA shows a decreased level of
expression after transfection with either Ski construct. C: qRT-PCR of similarly transfected cells
quantifying the levels of ID3 mRNA, a target of bone morphogenetic protein (BMP) signaling,
showing that there is decreased levels of expression with Ski over expression but not with over
expression of the Ski-APRG construct. Error bars represent standard error of the mean. mRNA
levels were normalized to the GAPDH mRNA levels. n ¼ 3. *P < 0.05, **P < 0.01.

all-trans RA in the presence of the
cycloheximide.
Inhibition of aldh1a2 was done by
treatment with either 20 mM diethylaminobenzaldehyde (DEAB) (Cartry
et al., 2006) or 120 mM citral (Begemann et al., 2004). Inhibition of cyp26
was done using 50 mM ketoconazole
(Lutz et al., 2001). Both inhibitor
treatments were from embryonic
stage 20 to 28 at which time the
embryos were fixed for in situ hybridization. As with the retinoid treatments, the carrier control for the
inhibitors was 1 ml/ml DMSO.

substrate. Embryos were post-fixed in
4% paraformaldehyde for 20 min and
endogenous pigment was bleached
using 0.5% hydrogen peroxide, 5%
formamide, and 0.5% standard saline
citrate for several hours. Embryo
images were obtained using Northern
Eclipse software (Empix Imaging,
Mississauga, Canada) on a Leica
MZ12 dissecting microscope.

In Situ Hybridization
Whole-mount in situ hybridizations
were performed according to standard
protocols (Harland, 1991) with slight
modifications (Deimling and Drysdale, 2009). Antisense riboprobes for
ski (Amaravadi et al., 1997) and
cpy26a1 (Hollemann et al., 1998)
were labeled with digoxigenin-UTP
(Roche Diagnostics) without incorporation of radio-labeled nucleotides.
BM Purple (Roche Diagnostics) was
used as the alkaline phosphate

Fig. 8. A proposed model of retinoic acid
(RA) signaling negative feedback loops. The
best understood feedback loop is when RA
directly activates genes that encode enzymes
that reduce the level of retinoic acid as exemplified by cyp26a1. Our results suggest that
RA can also activate genes such as ski allowing ski to act at the level of the RA receptors
to attenuate signaling.
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Xenopus qRT-PCR
A total of eight embryos were used
per treatment group. Embryos were
homogenized at earlier stages (<
stage 26) using the lysis buffer provided in the Qiagen RNeasy mini Kit
according to manufacturer’s instructions. Later staged embryos used a
homogenization buffer consisting of 4
M guanidine thiocyanate, 25 mM sodium citrate, 0.5% N-lauroyl-sarcosine, and 0.1 M b-mercaptoethanol.
After homogenization, 1/10th of the
volume of 2 M sodium acetate (pH 4)
was added followed by a 1:1 volume of
phenol:chloroform. This was then centrifuged for 5 min at 14K. The aqueous phase was removed, placed in a
fresh tube and 2.5 the volume of
70% ethanol was added. This solution
was placed in the Qiagen RNeasy
spin columns and the RNA purified
according to manufacturer’s instructions. RNA concentration and quality
was then measured using a spectrophotometer and a 1% agarose in TAE
gel containing ethidium bromide.
cDNA was synthesized using Superscript II Reverse Transcriptase (Invitrogen) with OligodT12–16 primers
(Invitrogen) and RNase Out (Invitrogen). Xenopus RNA (500 mg) was isolated and used in the RT reaction.
Primers for qPCR were designed
using Primer3 or published primer
sequences were used as cited: Xenopus ski - F: TGTGACAAAGGCTGTG
AAGC, R: CAGAGCTGTTCCTGG
AGGTC, Xenopus cyp26a1 – F: GCT
GCCACGTCCCTCACCTCTT R: GCC
GATGCAGCACCTCACTCCA, Xenopus id3 – F: AAAGCCATCAGCCC
AGTG, R: AGTGGCAGACGCTGG
TGT (Nichane et al., 2008), Xenopus
hist1h4a - F: CGGGATAACATTCAG
GGTA R: TCCATGGCGGTAACTGTC
(Sindelka et al., 2006). In a study of
housekeeping genes in Xenopus, it
was also found that normalization
using these genes was problematic
(Sindelka et al., 2006) but identified
hist1h4a as giving the most consistent results other than simply using
total RNA. Our tests supported this
finding; thus, hist1h4a mRNA levels
were used to normalize qPCR data.
qPCR was performed according to
manufacturer’s protocols for Brilliant
SYBR Green Master mix (Agilent
Stratagene).
The
denaturation



temperature was 94 C, with an

annealling temperature of 55 C and

elongation at 72 C. All qPCR experiments used a minimum of three ranging to a maximum of five replicates.
All statistics were performed with
GraphPad Prism4 using a one-way
analysis of variance (ANOVA) and a
95% confidence interval with a post
hoc Tukey’s test.

Cell Culture
Human keratinocyte (HaCaT) cells
were grown in 5% fetal bovine serum
(FBS) (Wisent) in DMEM, 5% CO2 at

37 C reaching approximately 75–80%
confluence before RNA and protein
isolation. HaCaT cells were incubated
for 18 hr before treatment with 5%
charcoal-stripped serum in DMEM.
The cells were then treated using 1
mM all-trans RA or 1 mM pan-RA antagonist (Allergan 193109; Teng et al.,
1997) dissolved in DMSO. A 1 ml/ml
DMSO treatment was used as a carrier control. RNA was isolated using
the Qiagen RNeasy mini Kit according to manufacturer’s instructions.
RNA concentration and quality was
measured using a Nanodrop spectrophotometer and also visualized using
a 1% agarose in TAE gel containing
ethidium bromide. Transfection of
plasmids was done using Lipofectamine according to manufacturers’
instructions.
cDNA was synthesized using Superscript II Reverse Transcriptase (Invitrogen) with Oligo dT12–16 primers
(Invitrogen). Primers for qPCR
included SKI F: AAAGAGCTCTCCC
CACACCT, R: GGGTGTCCACAGT
CAGCTTC (designed using Primer3);
CYP26A1 F: TTTGGAGGACACGA
AACCAC, R: CAGCATGAATCGGTC
AGGAT (Zaitseva et al., 2007); ID3 F:
TGGTTTTCTTTCTCTTTGGGG, R:
CGGGAGTAGCAGTGGTTCAT; GA
PDH F: CATGAGAAGTATGACAAC
AGC, R: AGTCCTTCCACGATACCAA
AG (Lin et al., 2005).
Using DMEM media without serum
in six-well plates (Fisher Scientific),
HaCaT cells were transfected with 2
mg plasmid DNA using Lipofectamine
(Invitrogen). Cells were assayed after
24 hr. Cells were rinsed twice in cold
phosphate buffered saline (PBS) and
lysed with RIPA buffer containing 1
mM sodium vanadate, 10 mM sodium

pyrophosphate, 10 mM NaF, 1 mM
phenylmethylsulfonyl
fluoride
(PMSF), and 4% protease inhibitor
cocktail (Sigma). For Western blots of
the Flag-tagged Ski products, 100 mg
of protein were loaded per lane and
separated on a 7.5% polyacrylamide
gel followed by transfer to polyvinylidene fluoride (PVDF) membrane. Primary antibodies used for Western
blots were Anti-FLAG (ThermoScientific) and anti-b-actin (Santa Cruz).
The protein on the membrane then
was probed with horseradish peroxidase (HRP) -coupled secondary antibodies and detected using the
LumiGLO Chemiluminescent Kit
(KPL) on a Versadoc gel documentation system.
To detect endogenous SKI in
HaCaT cells after RA exposure, cells
were seeded to 6-cm culture dishes at
5  105 cells and the following day
media was replaced with charcoalstripped serum-containing media. On
the following day, cells were treated
with 1 mM RA and total protein was
isolated using RIPA lysis buffer containing protease inhibitors. Western
blotting was performed on 50 mg total
protein using anti-Ski antibody
(Kamiya Biomedical, clone G8,
1:1,000 dilution in 5% bovine serum
albumin/Tris buffered saline [TBS]
Tween 20) incubated overnight at 4 C
followed by detection using antimouse IgG-HRP secondary antibody
(GE Healthcare). Anti-actin antibody
(1:1,000 in 5% skim milk/TBS-Tween
20; Sigma) and anti-rabbit IgG-HRP
secondary antibody (GE Healthcare)
were used to control for protein loading. Chemiluminescence detection
was performed using Luminata Forte
Western HRP Substrate (Millipore)
and the BioRad ChemiDoc MP Imaging System.
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